radioligand therapies

Apr 15, 2026

The global healthcare industry is transforming precision medicine and targeted therapies redefine the way complex diseases, especially cancer, are treated. One of the most promising innovations emerging from nuclear medicine is Radioligand Therapies (RLTs), a treatment modality that combines molecular targeting wit...

Apr 13, 2026

Summary  With FDA-approved products LUTATHERA and PLUVICTO, both beta-emitters, Novartis has established itself as an industry frontrunner. Over 15 ongoing or planned trials and several next-generation candidates in development in Novartis RLT pipeline. Rivals include AstraZeneca, Bayer, Eli Lilly, C...

Apr 01, 2026

Radiopharmaceuticals are a cornerstone of precision medicine, enabling clinicians to visualize disease at the molecular level while simultaneously delivering targeted radionuclide therapy to tumors and other pathological tissues. Their dual diagnostic and therapeutic potential has positioned them as a transformativ...

Mar 20, 2026

Summary Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production. Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive lan...

Mar 09, 2026

Summary  Radioligand therapy is becoming a crucial component of cancer treatment. Approved radioligand therapy includes LUTATHERA (for GEP-NETs), XOFIGO, PLUVICTO (both for prostate cancer), and ZEVALIN (for follicular B-cell non-Hodgkin's lymphoma). Leading companies such as Novartis, Curium Pharma,...

Nov 29, 2024

Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology comm...

Apr 26, 2024

2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects.  On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...